Clinical Trials
In the twenty-five plus years since its establishment, the physicians at the Lancaster Cancer Center have witnessed an almost exponential growth in the number and type of cancer treatments available. These treatments are used in our office only after completing the extensive clinical trials process overseen by the Food and Drug Administration. Now the Lancaster Cancer Center is expanding its own participation in this clinical trials process, both to further research in cancer treatments and to offer this cutting edge option to our patients.
When a patient at the Lancaster Cancer Center participates in a clinical trial, he or she always receives treatment for his or her disease. In a clinical trial, this treatment might be a new drug, a new dosing schedule of an established drug, or a new combination of established drugs. Whatever the trial in which they may choose to participate, clinical trials patients at the Lancaster Cancer Center know that they are both receiving the best possible care and helping all those who also suffer from this disease.
We are a proud member of the ACORN (Accelerated Community Oncology Research Network) which currently includes over 150 oncology investigators in progressive oncology practices throughout the United Staes and abroad that are dedicated to clinical research. This collaboration of select community oncology clinics provides access to the most promising clinical trials available anywhere. As such, ACORN members offer patients opportunities to participate in the most promising clinical research studies that once were only avaiable in academic research settings.
All ACORN member practices share the same three Rs of research - the Right trial for the Right patient for the Right reason.
Current Clinical Trials at the Lancaster Cancer Center
Protocol: AVF 4349n Observational Trial (Metastatic Breast Cancer)
Description: AN observational study of treatment patterns and safety outcomes for metastatic or locally recurrent breast cancer.
Protocol: 3144A2-3003-WW (Metastatic Breast Cancer)
Description: A phase III, randomized, open-label study of Neratinib vs. Lapatinib plus Capecitabine for the treatment of ErbB-2+ locally advanced or metastatic breast cancer.
Protocol: CZOL446E2352 Treatment Trial (Metastatic Breast Cancer)
Description: A prospective, randomized, double-blind, stratified, multi-center, 2-arm trial of the continued efficacy and safety of Zometa (every 4 weeks vs. every 12 weeks) in patients with documented bone metastases from breast cancer
Protocol: 3144A2-3004-WW Treatment Trial (Adjuvant Breast Cancer)
Description: A randomized, double-blind, placebo-controlled trial of neratinib (HKI-272) after trastuzumab in women with early-stage HER-2/neu overexpressed/amplified breast cancer.
Protocol: EZN-2208-04 Treatment Trial (Metastatic Colon Cancer)
Description: A phase III, randomized, double-blind, placebo-controlled study of pegfilgrastim administered to subjects with newly diagnosed, locally-advanced or metastatic colorectal cancer treated with bevacizumab and either 5-fluorouracil, oxaliplatin, leucovorin (FOLFOX) or 5-fluorouracil, irinotecan, leucovorin (FOLFIRI).
Protocol: 20080259 Treatment Trial (Metastatic Colon Cancer)
Description: A phase III, randomized, double-blind, placebo-controlled study of pegfilgrastim administered to subjects with newly diagnosed, locally-advanced or metastatic colorectal cancer treated with bevacizumab and either 5-fluorouracil, oxaliplatin, leucovorin (FOLFOX) or 5-fluorouracil, irinotecan, leucovorin (FOLFIRI).
Protocol: MAGRIT109493 Treatment Trial (Adjuvant Non-Small Cell Lung Cancer)
Description: A double-blind, randomized, placebo-controlled phase III study to assess the efficacy of recMAGE-A3 +AS15 Antigen-Specific Cancer Immunotherapeutic as adjuvant therapy in patients with resectable MAGE-A3-positive Non-Small Cell Lung Cancer.
Protocol: H3E-US-S130 Treatment Trial (Metastatic Non-Small Cell Lung Cancer)
Description: A randomized, open-label, phase III study of pemetrexed plus carboplatin followed by maintenance pemetrexed versus paclitaxel plus carboplatin and bevacizumab in patients with advanced Non-Small Cell Lung Cancer of Nonsquamous Histology.
Protocol: OMB113676 Treatment Trial (Non-Hodgkin’s Lymphoma)
Description: A phase III, randomized, open label study of single agent ofatumumab vs. single agent rituximab in follicular lymphoma relapsed after rituximab-containing therapy.
Protocol: CTKI258A2204 Treatment Trial (Multiple Myeloma)
Description: A phase II, multi-center, non-randomized, open-label study of TKI258 in patients with relapsed or refractory multiple myeloma, who are with or without t(4:14) translocation.